Why Is ARCUS BIOSCIENCES IN (RCUS) Stock Down Today?

Arcus Biosciences stock fell 7.41% to $26.38 on Thursday, driven by a sharp intraday decline following an initial positive open. The stock opened at $28.65 but dropped to a session low of $26.32 by the close, with volume reaching 1.2 million shares, in line with its 3-month average. The move came amid recent news including new employment inducement grants and a key milestone in a pancreatic cancer trial.

What Happened

Arcus Biosciences announced new employment inducement grants, including 13,200 restricted stock units and options with an exercise price of $29.06. This activity occurred under its 2020 plan and followed a recent update on a pancreatic cancer trial, which noted a key data milestone. The company also presented at Citigroup’s Biopharma Back to School Summit 2026. Despite these developments, the stock fell sharply in the afternoon session. Recent insider transactions show three sales totaling $3.0 million, with the most recent filing on August 24. Additionally, a congressional trade disclosed on May 15 showed a sale between $15,001 and $50,000.

What The Data Shows

The stock opened with a small positive gap but quickly reversed course. Volume was typical at 1.2 million shares, and the price trend shows a steep intraday drop. The 52-week tape recorded 31 fresh 52-week lows on September 10, indicating broader selling pressure. The stock has traded between $11.10 and $31.73 over the past year, with a current market cap of $3.7 billion. Despite a recent earnings beat in Q2, the company remains unprofitable with a trailing twelve-month EPS of -3.86 and a net margin of -393.2%.

What To Watch

The company is scheduled to present at Citigroup’s Biopharma Back to School Summit 2026, which may provide further insight into its pipeline. Coverage breadth and analyst price targets will be key to watch as the stock approaches its next major data readouts.